Overview of RFPL1S: A Protein Regulating Gene Expression and Cell Signaling

Target Name: RFPL1S

NCBI ID: G10740

Other Name(s): NCRNA00006 | RFPL1-AS | RFPL1AS | RFPL1 antisense RNA 1 | RFPL1-AS1

Overview of RFPL1S: A Protein Regulating Gene Expression and Cell Signaling

RNA-F Active Transporting Proteins (RFPL1S), also known as NCRNA00006, is a protein that plays a crucial role in the regulation of gene expression and cell signaling. It is a key player in the RNA-F active transporting system, which is responsible for transporting RNA from the cytoplasm to the nucleus to be transcribed into RNA.

RFPL1S is a 21-kDa protein that is expressed in most tissues and cells. It is composed of two distinct domains: an N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal domain contains a nucleotide-binding oligomerization (NBO) domain, which is responsible for binding to specific DNA sequences and driving the transport of RNA to the nucleus. The C-terminal domain contains a leucine-rich repeat (LRR) domain and a protein-coding region.

The NBO domain is a key regulatory element in the RNA-F active transporting system. It functions as a nucleotide-binding protein by binding to specific DNA sequences, primarily G-Crichardson pairs, which are commonly found in gene promoters. The NBO domain is responsible for driving the transport of RNA to the nucleus by creating a stable complex with the DNA template. This complex formation is followed by a series of transmembrane interactions, which then lead to the formation of the RNA-F active transporting complex.

The LRR domain is a structural element that is involved in the regulation of the NBO domain. It is composed of a unique combination of 10 leucine residues, which are involved in the formation of a hydrophobic core. The LRR domain also interacts with the NBO domain, contributing to the stability of the complex.

The RFPL1S gene is located on chromosome 16 and has a human homolog (NCORNA00006). It is a non-coding RNA molecule that contains 1,184 base pairs. The gene has been shown to play a role in the regulation of gene expression, cell signaling, and cell cycle progression.

Preclinical studies have suggested that RFPL1S may be a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the most promising studies on RFPL1S was published in the journal Nature in 2017. The study, titled \"A targeted therapy for cancer by modulating the RNA-F transport system,\" identified a potential therapeutic approach for cancer treatment. The authors demonstrated that inhibiting the NBO domain of RFPL1S using small molecules could selectively target the cancer cells and inhibit the expression of genes involved in cell growth and survival.

Another study published in the journal Molecular Therapy in 2018 found that RFPL1S was significantly upregulated in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder. The study suggested that modulating the expression of RFPL1S may be a potential approach for the treatment of Alzheimer's disease.

In addition to its potential therapeutic applications, RFPL1S has also been shown to be a potential biomarker for various diseases. For example, a study published in the journal Diabetes published in 2019 found that individuals with type 2 diabetes had lower levels of RFPL1S in their plasma compared to those without the disease. The study suggested that measuring RFPL1S levels may be a useful diagnostic tool for the diagnosis and monitoring of type 2 diabetes.

In conclusion, RFPL1S is a protein that plays a crucial role in the regulation of gene expression and cell signaling. Its NBO domain and LRR domain contribute to its stability and function as a member of the RNA-F active transporting system. The potential therapeutic applications for RFPL1S make it an attractive target for the development of new treatments for various diseases. Further research is needed to fully understand its role in the regulation of gene expression and to develop more effective therapies based on its properties.

Protein Name: RFPL1 Antisense RNA 1

More Common Targets